Elizabeth Iorns
13 statements across 3 episodes · 8 bullish · 4 bearish · 2 people on the record · first statement Feb 23, 2015 by Elizabeth Iorns · said 3 times in 2 episodes since 2018 · across every show →
On the record as a speaker too: Elizabeth Iorns's record, appearances and statements → this page counts the times other people say the name.
Mentions by year
brought up most by Adora Cheung (2), Craig Cannon (1)
tap a year for its mentions
2019 2 mentions in 1 episode
Everything said about Elizabeth Iorns, oldest first
Feb 23, 2015 bullish
Sep 13, 2017 negative
Iorns: Postdocs face a severe shortage of academic faculty jobs
“And there's this pretty well-known phenomenon called the postdocalypse that Ethan Pilstein came up with, which is this concept that there's so many postdocs now and no jobs for them. So there's just nowhere for them to go in terms of staying as An assistant pr…”
Sep 13, 2017 positive
Iorns: All marketed drugs require commercial industry to reach patients
“Because the reality is, you know, all innovations that come to market are through industry. So, you know, you don't see drugs on the market that came from academia. They were all, many of them discovered in the earliest phases, the basic research was done in a…”
Sep 13, 2017 positive
Iorns: AI predicting preclinical efficacy and toxicity is highly promising
“For me, the applied area, that's probably one of the more interesting areas, is looking at things like the application of artificial intelligence in the biological sector, so there's some pretty interesting work that's occurring around how to be better at pred…”
Sep 13, 2017 positive
Iorns: Clinical trials are shifting toward testing efficacy endpoints in Phase 1
“Historically people would do, you know, phase one, which is basically just like a dose escalation study where you're just looking for toxicity. And then you would do a much larger study afterwards where you're looking for efficacy, and so that's really time co…”
Oct 3, 2018 negative
Iorns: Biotech founders often delay the killer experiment out of fear
“One mistake I have seen people make is just, and it's, I think all startup founders kind of do this, is like, not doing the killer experiment, like, not actually just cutting to the chase and saying, okay, these are just the minimal things I need to do to trul…”
Oct 3, 2018 negative
Iorns: Scientific founders should not prioritize finding a business co-founder
“No, I don't think that should be a goal. I think I actually do have a business co-founder, so you would probably be mad that I say that, but, and he's great, and I literally couldn't have built Science Exchange without him, but not because of his business back…”
Oct 3, 2018 positive
Oct 3, 2018 positive
Iorns: Research market information inefficiency creates high-margin marketplace opportunities
“So that was something that was a big a big learning point for me at that time point was you could actually create a company that had margin in that space because the market was so inefficient due to the lack of information.”
Oct 3, 2018 positive
Iorns: Science startups should wait for grant-funded R&D before joining accelerators
“Actually I do think a good time to join is once you've already generated a lot of the R&D from grant-funded work, because you don't want to spend years and all of this money trying to You know, pursue a research hypothesis. You really want to be in the develop…”
Oct 3, 2018 bullish
Oct 3, 2018 negative
Oct 3, 2018
Iorns: Scientific experiments often have 10x price differences for equivalent results
“So for example I was seeing literally 10 times price differences for an equivalent experiment because people really just didn't have access to what should it actually cost. And we see that still on Science Exchange today is that when people go and look for mul…”